{"nct_id":"NCT04209205","title":"Study to Demonstrate the Efficacy, Safety and Tolerability of Intravenous Secukinumab up to 52 Weeks in Subjects With Active Psoriatic Arthritis","status":"COMPLETED","status_verified_date":"2025-05","start_date":"2020-01-29","start_date_type":"ACTUAL","primary_completion_date":"2022-05-17","primary_completion_date_type":"ACTUAL","completion_date":"2022-05-17","completion_date_type":"ACTUAL","phases":["PHASE3"],"tickers":["NVS"]}